These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

154 related items for PubMed ID: 28192480

  • 1. mTOR activity in AIDS-related diffuse large B-cell lymphoma.
    Browne SH, Diaz-Perez JA, Preziosi M, King CC, Jones GA, Jain S, Sun X, Reid EG, VandenBerg S, Wang HY.
    PLoS One; 2017; 12(2):e0170771. PubMed ID: 28192480
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Activation of the PI3K/AKT/mTOR pathway in diffuse large B cell lymphoma: clinical significance and inhibitory effect of rituximab.
    Xu ZZ, Xia ZG, Wang AH, Wang WF, Liu ZY, Chen LY, Li JM.
    Ann Hematol; 2013 Oct; 92(10):1351-8. PubMed ID: 23636313
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Mammalian target of rapamycin inhibition induces cell cycle arrest in diffuse large B cell lymphoma (DLBCL) cells and sensitises DLBCL cells to rituximab.
    Wanner K, Hipp S, Oelsner M, Ringshausen I, Bogner C, Peschel C, Decker T.
    Br J Haematol; 2006 Sep; 134(5):475-84. PubMed ID: 16856892
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Prognostic significance and therapeutic potential of the activation of anaplastic lymphoma kinase/protein kinase B/mammalian target of rapamycin signaling pathway in anaplastic large cell lymphoma.
    Gao J, Yin M, Zhu Y, Gu L, Zhang Y, Li Q, Jia C, Ma Z.
    BMC Cancer; 2013 Oct 10; 13():471. PubMed ID: 24112608
    [Abstract] [Full Text] [Related]

  • 10. [Study on activation of AKT/mTOR pathway in anaplastic large cell lymphoma].
    Li JF, Li GD, Gu L, Liu WP, Li FY, Liao DY, Ma ZG.
    Zhonghua Xue Ye Xue Za Zhi; 2008 Oct 10; 29(10):649-53. PubMed ID: 19176054
    [Abstract] [Full Text] [Related]

  • 11. Characteristic mTOR activity in Hodgkin-lymphomas offers a potential therapeutic target in high risk disease--a combined tissue microarray, in vitro and in vivo study.
    Márk Á, Hajdu M, Váradi Z, Sticz TB, Nagy N, Csomor J, Berczi L, Varga V, Csóka M, Kopper L, Sebestyén A.
    BMC Cancer; 2013 May 22; 13():250. PubMed ID: 23693095
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The mTOR downstream regulator (p-4EBP1) is a novel independent prognostic marker in ovarian cancer.
    Alabdullah ML, Ahmad DA, Moseley P, Madhusudan S, Chan S, Rakha E.
    J Obstet Gynaecol; 2019 May 22; 39(4):522-528. PubMed ID: 30712414
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Activity and complexes of mTOR in diffuse large B-cell lymphomas--a tissue microarray study.
    Sebestyén A, Sticz TB, Márk A, Hajdu M, Timár B, Nemes K, Nagy N, Váradi Z, Kopper L.
    Mod Pathol; 2012 Dec 22; 25(12):1623-8. PubMed ID: 22899290
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. PI3K/AKT/mTOR pathway activation in primary and corresponding metastatic breast tumors after adjuvant endocrine therapy.
    Beelen K, Hoefnagel LD, Opdam M, Wesseling J, Sanders J, Vincent AD, van Diest PJ, Linn SC.
    Int J Cancer; 2014 Sep 01; 135(5):1257-63. PubMed ID: 24501006
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.